January 19, 2021, Vol 325, No. 3, Pages 205-316
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines
Steven Joffe, MD, MPH
free access has active quiz has multimedia has audio
JAMA. 2021;325(3):221-222. doi:10.1001/jama.2020.25127
This Viewpoint discusses the ethics of including a placebo arm in randomized trials of coronavirus vaccines once authorized vaccines have become widely available, and proposes use of adaptive platform trial designs as an optimal approach to nimbly and ethically compare future investigational COVID-19 vaccines with proven effective ones.